BioSpace News Archive

PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA ® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.

Vaxart, Inc. announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 9, 2022 at 10:30 a.m. ET.

MiMedx Group, Inc., a transformational placental biologics company, addressed the highly misleading presentation published by Prescience Point on May 31, 2022, which mischaracterizes important facts and relies on outdated and irrelevant information.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that its virtual Annual Meeting of Stockholders (the “Annual Meeting”) will be held on Thursday, June 16, 2022 at 1:00 p.m. PT.

Previon has achieved ISO 13485 certification from NSF-ISR, an NSF company.

IASO Biotherapeutics (“IASO Bio”), and Innovent Biologics, Inc. (“Innovent,” HKEX: 01801), today jointly announced that the China National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for Equecabtagene Autoleucel (IASO Bio R&D code: CT103A, Innovent R&D code: IBI326).

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced theCompany’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will present a company overview at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 11:00 a.m.

KeifeRx , an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases announced today that its Chief Executive Officer, Chris Hoyt, will present at BIO International Convention 2022 being held June 13-16, 2022 in San Diego.

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that Jill M. Mooney, Ph.D., has joined as Senior Vice President of Research and Development (R&D).